Skip to content

A Registry Study on Hospitalized Patients With Community-acquired Pneumonia in Real-life of China

Evaluating the Adherence to Guidelines' Empirical Antibiotic Recommendations and Outcome of Patients Admitted to a Hospital Ward With a Diagnosis of Community-acquired Pneumonia

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02492425
Acronym
CAP-China
Enrollment
3000
Registered
2015-07-08
Start date
2016-01-31
Completion date
2018-05-31
Last updated
2015-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community Acquired Pneumonia

Keywords

Community Acquired Pneumonia, Healthcare Associated Pneumonia

Brief summary

The purpose of this study is to evaluate the disease burden of hospitalized patients with CAP and HCAP in real life of China

Detailed description

In China, the data about current management of patients hospitalized with community acquired pneumonia (CAP) in the real-life setting is not available,type of pneumonia, selection of initial antibiotic, time to clinical stability, antibiotic choice anf modification,clinical outcomes and costs remain unclear. In this study, we will collect comprehensive information on CAP and healthcare associated pneumonia (HCAP) management patterns to evaluate the disease burden of hospitalized patients with CAP and HCAP in real life of China .to analyze microbiological characteristics,clinical manifestations,antibiotic regimens ,adherences to guidelines and effect on outcome in different groups of patients with CAP (\> and = 65 years, different comorbidities ,risk factors) ,to investigate microbiological characteristics,clinical manifestations,antibiotic regimens ,adherences to guidelines and effect on outcome in different groups of disease severity with CAP ,to provide the difference on microbiological characteristics,clinical manifestations,antibiotic regimens ,and outcome between patients with CAP and HCAP ,to understand the current situation of antibiotic regimen ,to evaluate influence of different antibiotic regimens on prognosis.

Interventions

None listed

Sponsors

Capital Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients \> or = 14 years of age * Patient meets the criteria of community acquired pneumonia * Patient meets the criteria of healthcare-associated pneumonia * Informed consent to participate in the study is provided

Exclusion criteria

* Patients participating in a clinical trial or other intervention studies * Patients \<14 years of age * Patient meets the criteria of hospital acquired pneumonia * Known active tuberculosis or current treatment for tuberculosis * Non-infectious pulmonary diseases (e.g. pulmonary embolism, pulmonary edema, pulmonary vasculitis, interstitial pneumonia) * HIV positive

Design outcomes

Primary

MeasureTime frameDescription
initial antibiotic treatment failure rate72 hoursa change in antibiotic therapy due to worsening signs or symptoms of infection or lack of clinical improvement after first dose use of antibiotics to 72h
in-hospital clinical failure rateTime from date of admission to discharge up to 1 week1)a change in antibiotic therapy due to worsening signs or symptoms of infection or lack of clinical improvement, 2) in-hospital mortality, 3) recurrence, defined as signs or symptoms of infection after completion of therapy requiring re-initiation of antibiotics
30-day post-discharge clinical failure ratedischarge up to 5 weeksrate of re-hospitalization due to pulmonary infection and death during the follow-up period at 30 days post-discharge from hospital

Secondary

MeasureTime frameDescription
Days of each antimicrobial therapy6 weeksTime from date of first administration on admission to hospital to date of discontinuation (or to date of censoring, whichever comes first) upto a maximum of 30 days post-discharge follow-up for each antibiotic
Duration of intravenous antimicrobial therapy2 weeksTime from the first dose of intravenous antibiotics to date of stop of intravenous antibiotics ,participants will be followed for the duration of hospital stay
Hospital length of stay2 weeksPatients will be asked about hospitalization, date, Patients will be asked about hospitalization, date, participants will be asked about the time of admission and discharge
Duration of oral antimicrobial therapy2 weeksTime from date of administration of first antibiotic to date of discontinuation of last antibiotic
Duration of antimicrobial therapy6 weeksTime from date of administration of first antibiotic to date of discontinuation of last antibiotic (or to date of censoring, whichever comes first) upto a maximum of 30 days post-discharge from hospital post discharge from hospital

Countries

China

Contacts

Primary ContactBin Cao, MD
caobin_ben@163.com86-010-84206264
Backup ContactLI Gu, MD
guli2013227@foxmail.com.cn86-010-85231514

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026